These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 18844493)

  • 21. Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
    Asaba Y; Hiramatsu K; Matsui Y; Harada A; Nimura Y; Katagiri N; Kobayashi T; Takewaka T; Ito M; Niida S; Ikeda K
    Bone; 2006 Dec; 39(6):1276-82. PubMed ID: 16942925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
    LoCascio V; Braga V; Bertoldo F; Bettica P; Pasini AF; Stefani L; Moro L
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):47-51. PubMed ID: 8050131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
    Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
    J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.
    Khan SA; Kanis JA; Vasikaran S; Kline WF; Matuszewski BK; McCloskey EV; Beneton MN; Gertz BJ; Sciberras DG; Holland SD; Orgee J; Coombes GM; Rogers SR; Porras AG
    J Bone Miner Res; 1997 Oct; 12(10):1700-7. PubMed ID: 9333131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
    Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
    Palacios S; Neyro JL; Ferrer J; Villero J; Cañada E; Redondo E; Caloto MT; Nocea G;
    Menopause; 2012 Jan; 19(1):67-74. PubMed ID: 21926927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A; Hannon R; Eastell R
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of alendronate therapy on bone turnover--results of a multicenter study].
    Payer J; Killinger Z; Masaryk P; Tomková S; Kmecová Z; Ondrejková J; Necas L; Smoterová J; Ondrejka P; Kratochvilová H
    Vnitr Lek; 2000 Oct; 46(10):689-92. PubMed ID: 11344627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markers of bone turnover in postmenopausal women receiving hormone replacement therapy.
    Hamwi A; Ganem AH; Grebe C; Kerschan-Schindl K; Preisinger E; Boschitsch E; Bieglmayer C
    Clin Chem Lab Med; 2001 May; 39(5):414-7. PubMed ID: 11434391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men.
    Fall PM; Kennedy D; Smith JA; Seibel MJ; Raisz LG
    Osteoporos Int; 2000; 11(6):481-5. PubMed ID: 10982162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
    Del Campo MT; González-Casaus ML; Aguado P; Bernad M; Carrera F; Martínez ME
    Osteoporos Int; 1999; 9(5):449-54. PubMed ID: 10550465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis.
    Gur A; Colpan L; Cevik R; Nas K; Jale Sarac A
    Clin Biochem; 2005 Jan; 38(1):66-72. PubMed ID: 15607319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid determination of free prolyl dipeptides and 4-hydroxyproline in urine using flow-gated capillary electrophoresis.
    Zhang N; Zhu Q; Gong M
    Anal Bioanal Chem; 2017 Dec; 409(30):7077-7085. PubMed ID: 28971239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG; Downs RW; Tucci JR; Harris ST; Weinstein RS; Licata AA; McClung MR; Kimmel DB; Gertz BJ; Hale E; Polvino WJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate.
    Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F
    Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
    Garnero P; Mulleman D; Munoz F; Sornay-Rendu E; Delmas PD
    J Bone Miner Res; 2003 Oct; 18(10):1789-94. PubMed ID: 14584889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women.
    Celik E; Guzel S; Abali R; Guzelant AY; Celik Guzel E; Kuçukyalcin V
    Minerva Med; 2013 Oct; 104(5):497-504. PubMed ID: 24101107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.